Skip to content

EMDR for Fear of Cancer Recurrence in Patients with Familial Melanoma. A waiting list control trial

EMDR for Fear of Cancer Recurrence in Patients with Familial Melanoma. A waiting list control trial - FAME

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON55902
Enrollment
30
Registered
2022-05-19
Start date
2023-12-11
Completion date
Unknown
Last updated
2025-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

fear of cancer recurrence fear of melanoma

Interventions

EMDR is a psychological intervention that has historically been applied to the treatment of Post-Traumatic Stress Disorder (PTSD), but has since then been shown to be effective for a variety of anxi
van Rood & de Roos, 2009
Maroufi, Zamani, Izadikhah, Marofi, & O'Connor, 2016). With more than 25 randomized clinical trials, EMDR has been established as an evidence-based intervention for PTSD and PTSD symptomatology incl

Sponsors

Leids Universitair Medisch Centrum
Lead Sponsor

Eligibility

Age
18 Years to 64 Years

Inclusion criteria

Inclusion criteria: 18 years or older, diagnosed with familial melanoma, melanoma in the past five years, receive regular screenings at the department of dermatology of the LUMC, report high fear of cancer recurrence and have signed an informed consent.

Exclusion criteria

Exclusion criteria: obvious cognitive impairments and insufficient knowledge of the Dutch language. unstable doses of anxiolytics acute psychiatric disorder such as psychosis of suicidality

Design outcomes

Primary

MeasureTime frame
The total score of the Cancer Worry Scale (CWS) on T2 is the primairy outcome measure.

Secondary

MeasureTime frame
Secondary parameters are the effect of the EMDR treatment at 3 months follow-up (T3), quality of life measured with the EORTC-QLQ-C30

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)